The FDA-approved technology developed by HeartFlow can predict a patient's long-term risk of target vessel failure as well as more invasive treatments performed inside a cath lab. 

The FDA made a special announcement about its decision, describing the news as "a major advance for public health."

“Aspirin is no longer a one-size-fits-all preventive tool for older adults," according to one specialist with Michigan Medicine. 

Using CT to perform coronary artery calcium scoring on symptomatic chest pain patients can deliver significant value, according to a new data published in Radiology. 

The new software was also added to the FDA's Tap Pilot program, an honor reserved for “high-quality, safe, effective and innovative medical devices."

Data from nearly 9.9 million participants were included in the team’s final analysis. The group emphasized the important role governments can play in trying to reverse the world's reliance on these products. 

“It can be a challenging discussion to have with patients because there is evidence that cannabis has some therapeutic properties," one researcher said. "However, as suggested by this study, cannabis use also has significant cardiovascular risks.”  

Interventional cardiologists have been anticipating this news for quite some time. The device, the first of its kind, provides an alternative treatment option to repeat PCI or cardiac surgery for patients with coronary ISR.